BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37129737)

  • 1. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
    de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S
    J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
    de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
    J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
    Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
    J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
    Liau LM; Ashkan K; Brem S; Campian JL; Trusheim JE; Iwamoto FM; Tran DD; Ansstas G; Cobbs CS; Heth JA; Salacz ME; D'Andre S; Aiken RD; Moshel YA; Nam JY; Pillainayagam CP; Wagner SA; Walter KA; Chaudhary R; Goldlust SA; Lee IY; Bota DA; Elinzano H; Grewal J; Lillehei K; Mikkelsen T; Walbert T; Abram S; Brenner AJ; Ewend MG; Khagi S; Lovick DS; Portnow J; Kim L; Loudon WG; Martinez NL; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Giglio P; Gligich O; Krex D; Lindhorst SM; Lutzky J; Meisel HJ; Nadji-Ohl M; Sanchin L; Sloan A; Taylor LP; Wu JK; Dunbar EM; Etame AB; Kesari S; Mathieu D; Piccioni DE; Baskin DS; Lacroix M; May SA; New PZ; Pluard TJ; Toms SA; Tse V; Peak S; Villano JL; Battiste JD; Mulholland PJ; Pearlman ML; Petrecca K; Schulder M; Prins RM; Boynton AL; Bosch ML
    JAMA Oncol; 2023 Jan; 9(1):112-121. PubMed ID: 36394838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
    Hdeib A; Sloan AE
    CNS Oncol; 2015; 4(2):63-9. PubMed ID: 25768330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.
    Heugenhauser J; Galijasevic M; Mangesius S; Goebel G; Buchroithner J; Erhart F; Pichler J; Widhalm G; Stockhammer G; Iglseder S; Freyschlag CF; Oberndorfer S; Bordihn K; von Campe G; Czech T; Surböck B; Urbanic Purkart T; Marosi C; Felzmann T; Nowosielski M
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?
    Olivier T; Migliorini D
    Rev Neurol (Paris); 2023 Jun; 179(5):502-505. PubMed ID: 37012085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.
    Li ZC; Bai H; Sun Q; Li Q; Liu L; Zou Y; Chen Y; Liang C; Zheng H
    Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
    Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
    BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatiotemporal habitats from multiparametric physiologic MRI distinguish tumor progression from treatment-related change in post-treatment glioblastoma.
    Kim M; Park JE; Kim HS; Kim N; Park SY; Kim YH; Kim JH
    Eur Radiol; 2021 Aug; 31(8):6374-6383. PubMed ID: 33569615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
    Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
    NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
    Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
    Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?
    Soike MH; McTyre ER; Shah N; Puchalski RB; Holmes JA; Paulsson AK; Miller LD; Cramer CK; Lesser GJ; Strowd RE; Hinson WH; Mott RT; Johnson AJ; Lo HW; Laxton AW; Tatter SB; Debinski W; Chan MD
    Neuroradiology; 2018 Oct; 60(10):1043-1051. PubMed ID: 30094640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
    Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
    Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.